Urba, W.

trial vaccine cancer cancer vaccines combination agent phase development response study point activity fficacy patient product e fficacy trials e fficacy tumor end points drug administration outcome randomized development paradigm schedule design bene fit end point proof-of-principle paradigm center component safety disease population therapy cancer vaccine university progression number measure combination agent proof-of-principle trials e ffect marker assay biologic partner immunother fferent administration example antitumor toxicity bethesda cohort process volume research corporation criteria institute antitumor activity combination partner phd —food e ffects william phase 1 trials cytotoxic lippincott january wilkin antitumor e ffect —national control patient population cytotoxic agents testing san diego —university assessment